[Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-?B-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University

PubMedID: 28109099

Yao XR, Xia F, Tang WJ, Zhou BJ. [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-?B-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease]. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37(1):56-62.
OBJECTIVE
To investigate the effect of Hugan Qingzhi tablets on lipid metabolism and inflammation in rats fed on high-fat diet and explore the underlying mechanisms.

METHODS
Sixty male Sprague-Dawley rats were randomly divided into 6 groups, namely HFD group (with high-fat diet and distilled water), control group (with normal diet and distilled water), fenofibrate group (with high-fat diet and treatment with 0.1 g
RESULTS
At high and moderate doses, Hugan Qingzhi effectively decreased the levels of ALT, AST, TG and CHOL levels in the serum, lowered the hepatic levels of TNF-a, IL-6 and CRP, enhanced p-AMPK, and reduced the expression of SREBP-1c, FASN and Ac-NF-aB-p65 in the liver of rats fed on high-fat diet.

CONCLUSION
Hugan Qingzhi tablets alleviates hyperlipidemia and inflammation in rats fed with high-fat diet possibly by activating AMPK pathway and suppress NF-aB activity to arrest the progression of nonalcoholic fatty liver disease.